J&J reaches Stelara biosimilar settlement with Formycon, following deals with Amgen and Teva

Another biosimilar version of Johnson & Johnson’s Stelara has been delayed after the pharma giant inked a new agreement with two European drugmakers developing a biosimilar version of J&J’s top-selling drug.

Formycon and Fresenius Kabi announced the settlement Monday morning, saying that their experimental biosimilar candidate…
Click here to view original post